Furthermore, genetic heterogeneity of AML, such as upregulation of BCL2A1 and CLEC7A or mutations of PTPN11 and KRAS, confers resistance to VEN, which has not been considered (Zhang et al. 2020). This evidence concerns the gene CLEC7A and acute myeloid leukemia.